©
Steven Cornfield on Unsplash
While this is expected to improve with the second dose, this important finding may help influence the design of future vaccination strategies, with further work needed to determine the optimal interval between vaccine doses in certain groups.
The team from the University of Oxford’s MRC-Weatherall Institute of Molecular Medicine (MRC-WIMM) Molecular Haematology Unit studied 60 patients with chronic myeloid blood cancers under the care of the Myeloid Team at the Churchill Hospital, Oxford University Hospitals NHS Foundation Trust.
The study, published in the British Journal of Haematology, was supported by the NIHR Oxford Biomedical Research Centre.
Read the full story on the Radcliffe Department of Medicine website
The story is also featured on the NIHR Oxford Biomedical Research Centre website